159 related articles for article (PubMed ID: 11197347)
21. A Structure-Activity Relationship Comparison of Imidazodiazepines Binding at Kappa, Mu, and Delta Opioid Receptors and the GABA
Li G; Nieman AN; Mian MY; Zahn NM; Mikulsky BN; Poe MM; Methuku KR; Liu Y; Cook JM; Stafford DC; Arnold LA
Molecules; 2020 Aug; 25(17):. PubMed ID: 32854311
[TBL] [Abstract][Full Text] [Related]
22. Pharmacological characterization of the cloned kappa-, delta-, and mu-opioid receptors.
Raynor K; Kong H; Chen Y; Yasuda K; Yu L; Bell GI; Reisine T
Mol Pharmacol; 1994 Feb; 45(2):330-4. PubMed ID: 8114680
[TBL] [Abstract][Full Text] [Related]
23. High-affinity carbamate analogues of morphinan at opioid receptors.
Peng X; Knapp BI; Bidlack JM; Neumeyer JL
Bioorg Med Chem Lett; 2007 Mar; 17(6):1508-11. PubMed ID: 17276685
[TBL] [Abstract][Full Text] [Related]
24. Expression and localization of delta-, kappa-, and mu-opioid receptors in human spermatozoa and implications for sperm motility.
Agirregoitia E; Valdivia A; Carracedo A; Casis L; Gil J; Subiran N; Ochoa C; Irazusta J
J Clin Endocrinol Metab; 2006 Dec; 91(12):4969-75. PubMed ID: 16984994
[TBL] [Abstract][Full Text] [Related]
25. Delta, mu and kappa opioid receptor agonists inhibit dopamine overflow in rat neostriatal slices.
Schlösser B; Kudernatsch MB; Sutor B; ten Bruggencate G
Neurosci Lett; 1995 May; 191(1-2):126-30. PubMed ID: 7659278
[TBL] [Abstract][Full Text] [Related]
26. Pharmacological properties of bivalent ligands containing butorphan linked to nalbuphine, naltrexone, and naloxone at mu, delta, and kappa opioid receptors.
Peng X; Knapp BI; Bidlack JM; Neumeyer JL
J Med Chem; 2007 May; 50(9):2254-8. PubMed ID: 17407276
[TBL] [Abstract][Full Text] [Related]
27. [The mu, delta and kappa properties of various opioids].
Ohta S; Niwa M; Nozaki M; Hattori M; Shimonaka H; Dohi S
Masui; 1995 Sep; 44(9):1228-32. PubMed ID: 8523655
[TBL] [Abstract][Full Text] [Related]
28. Cinnamoyl derivatives of 7alpha-aminomethyl-6,14-endo-ethanotetrahydrothebaine and 7alpha-aminomethyl-6,14-endo-ethanotetrahydrooripavine and related opioid ligands.
Rennison D; Neal AP; Cami-Kobeci G; Aceto MD; Martinez-Bermejo F; Lewis JW; Husbands SM
J Med Chem; 2007 Oct; 50(21):5176-82. PubMed ID: 17887741
[TBL] [Abstract][Full Text] [Related]
29. Competitive displacement binding assay on rat brain sections and using a beta-imager: application to mu-opioid ligands.
Poisnel G; Quentin T; Barré L; Coquerel A; Debruyne D
J Neurosci Methods; 2006 Jun; 154(1-2):60-7. PubMed ID: 16423409
[TBL] [Abstract][Full Text] [Related]
30. Structural determinants of opioid activity in derivatives of 14-aminomorphinones: effects of changes to the chain linking of the C14-amino group to the aryl ring.
Rennison D; Moynihan H; Traynor JR; Lewis JW; Husbands SM
J Med Chem; 2006 Oct; 49(20):6104-10. PubMed ID: 17004724
[TBL] [Abstract][Full Text] [Related]
31. Further Optimization and Evaluation of Bioavailable, Mixed-Efficacy μ-Opioid Receptor (MOR) Agonists/δ-Opioid Receptor (DOR) Antagonists: Balancing MOR and DOR Affinities.
Harland AA; Yeomans L; Griggs NW; Anand JP; Pogozheva ID; Jutkiewicz EM; Traynor JR; Mosberg HI
J Med Chem; 2015 Nov; 58(22):8952-69. PubMed ID: 26524472
[TBL] [Abstract][Full Text] [Related]
32. Functional antagonism of mu-, delta- and kappa-opioid antinociception by orphanin FQ.
Mogil JS; Grisel JE; Zhangs G; Belknap JK; Grandy DK
Neurosci Lett; 1996 Aug; 214(2-3):131-4. PubMed ID: 8878101
[TBL] [Abstract][Full Text] [Related]
33. Characterization of kappa1-opioid receptor binding in human insular cortex.
Izenwasser S; Staley JK; Cohn S; Mash DC
Life Sci; 1999; 65(9):857-62. PubMed ID: 10465345
[TBL] [Abstract][Full Text] [Related]
34. Synthesis and evaluation of opioid receptor-binding affinity of elaeocarpenine and its analogs.
Kurasaki H; Okamoto I; Morita N; Tamura O
Bioorg Med Chem Lett; 2010 Mar; 20(5):1601-3. PubMed ID: 20144865
[TBL] [Abstract][Full Text] [Related]
35. Identification, structure-activity relationships and molecular modeling of potent triamine and piperazine opioid ligands.
Yongye AB; Appel JR; Giulianotti MA; Dooley CT; Medina-Franco JL; Nefzi A; Houghten RA; Martínez-Mayorga K
Bioorg Med Chem; 2009 Aug; 17(15):5583-97. PubMed ID: 19576786
[TBL] [Abstract][Full Text] [Related]
36. Endomorphin-1 discriminates the mu-opioid receptor from the delta- and kappa-opioid receptors by recognizing the difference in multiple regions.
Ide S; Sakano K; Seki T; Awamura S; Minami M; Satoh M
Jpn J Pharmacol; 2000 Aug; 83(4):306-11. PubMed ID: 11001176
[TBL] [Abstract][Full Text] [Related]
37. Molecular docking reveals a novel binding site model for fentanyl at the mu-opioid receptor.
Subramanian G; Paterlini MG; Portoghese PS; Ferguson DM
J Med Chem; 2000 Feb; 43(3):381-91. PubMed ID: 10669565
[TBL] [Abstract][Full Text] [Related]
38. Redoubling the ring size of an endomorphin-2 analog transforms a centrally acting mu-opioid receptor agonist into a pure peripheral analgesic.
Piekielna J; De Marco R; Gentilucci L; Cerlesi MC; Calo' G; Tömböly C; Artali R; Janecka A
Biopolymers; 2016 May; 106(3):309-17. PubMed ID: 27038094
[TBL] [Abstract][Full Text] [Related]
39. Conversion of delta-, kappa- and mu-receptor selective opioid peptide agonists into delta-, kappa- and mu-selective antagonists.
Schiller PW; Weltrowska G; Nguyen TM; Lemieux C; Chung NN; Lu Y
Life Sci; 2003 Jun; 73(6):691-8. PubMed ID: 12801590
[TBL] [Abstract][Full Text] [Related]
40. Different motivational effects induced by the endogenous mu-opioid receptor ligands endomorphin-1 and -2 in the mouse.
Narita M; Ozaki S; Ioka M; Mizoguchi H; Nagase H; Tseng LF; Suzuki T
Neuroscience; 2001; 105(1):213-8. PubMed ID: 11483313
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
